Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hydralazine in chronic CHF

K Chatterjee, J L Rouleau, B M Massie

    Acta Medica Scandinavica. Supplementum
    |January 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Oral hydralazine offers significant hemodynamic benefits for chronic heart failure patients, improving cardiac output and exercise performance. While long-term prognosis impact is unknown, preliminary data suggests potential survival advantages in severe cases.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction.

    The pharmacogenomics journal·2017
    Same author

    A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials.

    The pharmacogenomics journal·2016
    Same author

    Opinions, hopes and concerns regarding pharmacogenomics: a comparison of healthy individuals, heart failure patients and heart transplant recipients.

    The pharmacogenomics journal·2014
    Same author

    Effect of nesiritide in patients with acute decompensated heart failure.

    The New England journal of medicine·2011
    Same author

    Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine.

    American heart journal·2003
    Same author

    Prognostic importance of the oxidized product of catecholamines, adrenolutin, in patients with severe heart failure.

    American heart journal·2003
    Same journal

    Giving life, giving death: ethical problems of high-technology medicine.

    Acta medica Scandinavica. Supplementum·1988
    Same journal

    Potential importance of the muscles for the development of insulin resistance in obesity.

    Acta medica Scandinavica. Supplementum·1988
    Same journal

    Potential role of adipose tissue for the development of insulin resistance in obesity.

    Acta medica Scandinavica. Supplementum·1988
    Same journal

    Mechanisms associating body fat distribution to glucose intolerance and diabetes mellitus: window with a view.

    Acta medica Scandinavica. Supplementum·1988
    Same journal

    Physical training and changes in regional adipose tissue distribution.

    Acta medica Scandinavica. Supplementum·1988
    Same journal

    Hormonal abnormalities in obesity.

    Acta medica Scandinavica. Supplementum·1988
    See all related articles

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Chronic heart failure (CHF) presents significant challenges in managing cardiac function.
    • Identifying effective therapeutic agents to improve hemodynamic parameters is crucial.

    Purpose of the Study:

    • To evaluate the hemodynamic effects of oral hydralazine in patients with chronic CHF.
    • To assess the impact of hydralazine on cardiac performance at rest and during exercise.

    Main Methods:

    • The study investigated hemodynamic responses to oral hydralazine administration.
    • Patient cohorts included those with and without mechanical cardiac defects like mitral or aortic regurgitation.

    Main Results:

    • Hydralazine significantly increased cardiac output (CO) and stroke volume (SV).

    Related Experiment Videos

  • Systemic vascular resistance was substantially decreased.
  • Improved cardiac performance was observed both at rest and during exercise, with sustained effects in some patients.

    • Conclusions:

    • Oral hydralazine demonstrates beneficial hemodynamic effects in chronic CHF patients.
    • Therapy may improve cardiac performance and potentially offer a better prognosis in select severe CHF subsets.
    • Further research is needed to determine the long-term prognostic impact of hydralazine therapy.